Takeda's FY03/24 guidance suggests slowdown in earnings due to expiry of Azilva and Vyvanse. Recent new launches have seen strong uptake and the company is being too cautious not to disappoint market
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.